At EMPE Diagnostics, we are pioneering a new era in the healthcare sector with a focus on rapid, affordable, and accessible diagnostic solutions for infectious diseases. Our mission is to revolutionize global health by developing and delivering innovative diagnostics that address urgent healthcare challenges, particularly in regions with limited access to advanced medical technologies.
As an investor in EMPE Diagnostics, you are not only contributing to a company that has a significant growth trajectory but also becoming part of a mission to improve healthcare outcomes for millions worldwide. Our innovative products have the potential to make a tangible impact on public health by enabling faster, more accurate diagnoses, which can lead to better treatment outcomes, reduced healthcare costs, and improved quality of life.
Why Invest in EMPE Diagnostics?
1. Innovative Technology with Global Impact
EMPE Diagnostics specializes in molecular diagnostics, with a focus on rapid and low-cost solutions for infectious diseases like tuberculosis and drug-resistant pathogens. Our proprietary technologies enable healthcare providers to diagnose and treat patients more effectively, particularly in low-resource settings where traditional diagnostics are inaccessible. This global scalability and our focus on critical health issues position us at the forefront of the diagnostic revolution.
2. Proven Track Record and Expertise
Founded and led by industry pioneers and renowned experts in molecular biology, biochemistry, and healthcare management, EMPE Diagnostics has a solid foundation of scientific expertise. Our team has developed and patented innovative diagnostic solutions that are gaining recognition and adoption worldwide. With multiple spin-out companies and collaborations with top research institutions, EMPE Diagnostics is recognized as a leader in the biotech and healthcare space.
3. Strong Market Opportunity
The global diagnostics market is expected to grow exponentially in the coming years, driven by the increasing demand for precision medicine, the rise of drug-resistant infections, and the need for accessible healthcare solutions in developing countries. EMPE Diagnostics is uniquely positioned to capitalize on these trends by offering products that meet the needs of both developed and emerging markets.
4. Socially Responsible and Impact-Oriented
At the heart of EMPE Diagnostics is a commitment to social impact. Our solutions address some of the world’s most pressing health issues, particularly in underserved regions where early diagnosis can save lives. By investing in EMPE, you are not only backing a high-growth company but also supporting a mission to bring life-saving diagnostics to populations that need them the most.
5. Scalable Business Model
Our innovative diagnostic platforms are designed to be affordable, portable, and easy to use, ensuring that they can be rapidly deployed across a wide range of settings, from hospitals and clinics to remote locations. This scalability offers significant revenue potential, especially as we expand into new markets and partner with healthcare providers and governments around the world.
EMPE Diagnostics specializes in molecular diagnostics, with a focus on rapid and low-cost solutions for infectious diseases like tuberculosis and drug-resistant pathogens. Our proprietary technologies enable healthcare providers to diagnose and treat patients more effectively, particularly in low-resource settings where traditional diagnostics are inaccessible. This global scalability and our focus on critical health issues position us at the forefront of the diagnostic revolution.
2. Proven Track Record and Expertise
Founded and led by industry pioneers and renowned experts in molecular biology, biochemistry, and healthcare management, EMPE Diagnostics has a solid foundation of scientific expertise. Our team has developed and patented innovative diagnostic solutions that are gaining recognition and adoption worldwide. With multiple spin-out companies and collaborations with top research institutions, EMPE Diagnostics is recognized as a leader in the biotech and healthcare space.
3. Strong Market Opportunity
The global diagnostics market is expected to grow exponentially in the coming years, driven by the increasing demand for precision medicine, the rise of drug-resistant infections, and the need for accessible healthcare solutions in developing countries. EMPE Diagnostics is uniquely positioned to capitalize on these trends by offering products that meet the needs of both developed and emerging markets.
4. Socially Responsible and Impact-Oriented
At the heart of EMPE Diagnostics is a commitment to social impact. Our solutions address some of the world’s most pressing health issues, particularly in underserved regions where early diagnosis can save lives. By investing in EMPE, you are not only backing a high-growth company but also supporting a mission to bring life-saving diagnostics to populations that need them the most.
5. Scalable Business Model
Our innovative diagnostic platforms are designed to be affordable, portable, and easy to use, ensuring that they can be rapidly deployed across a wide range of settings, from hospitals and clinics to remote locations. This scalability offers significant revenue potential, especially as we expand into new markets and partner with healthcare providers and governments around the world.
Our Growth Strategy
1. Product Development and Expansion:
We are continuously investing in the development of new diagnostic tests to address a broader range of infectious diseases. Our product pipeline is robust, with several innovations in the works that will further enhance our market presence.
2. Strategic Partnerships:
EMPE Diagnostics is actively forging partnerships with healthcare providers, NGOs, and government organizations to ensure widespread adoption of our diagnostic solutions. These collaborations not only accelerate product rollout but also position us as a trusted partner in the global healthcare ecosystem.
3. Global Market Penetration:
While we have a strong presence in Europe and Asia, we are aggressively expanding our market reach to other regions, including Africa and South America, where the need for cost-effective diagnostics is greatest.
4. Sustainability and Innovation:
We are committed to sustainable business practices and continuous innovation. By integrating sustainability into our operations and product development, we ensure that our solutions have a long-lasting impact on both global health and the environment.
We are continuously investing in the development of new diagnostic tests to address a broader range of infectious diseases. Our product pipeline is robust, with several innovations in the works that will further enhance our market presence.
2. Strategic Partnerships:
EMPE Diagnostics is actively forging partnerships with healthcare providers, NGOs, and government organizations to ensure widespread adoption of our diagnostic solutions. These collaborations not only accelerate product rollout but also position us as a trusted partner in the global healthcare ecosystem.
3. Global Market Penetration:
While we have a strong presence in Europe and Asia, we are aggressively expanding our market reach to other regions, including Africa and South America, where the need for cost-effective diagnostics is greatest.
4. Sustainability and Innovation:
We are committed to sustainable business practices and continuous innovation. By integrating sustainability into our operations and product development, we ensure that our solutions have a long-lasting impact on both global health and the environment.
Financial Performance and Future Outlook
EMPE Diagnostics has demonstrated strong financial performance, with consistent growth in revenue and market share. Our strategic investments in R&D, coupled with our global expansion efforts, are expected to drive substantial revenue growth in the coming years. With increasing demand for our products and the growing emphasis on healthcare innovation, EMPE Diagnostics is poised for long-term success.
We are inviting forward-thinking investors to join us on this exciting journey as we continue to redefine the future of diagnostics. By investing in EMPE Diagnostics, you will be supporting a company that not only has the potential for significant financial returns but also a profound impact on global health.
We are inviting forward-thinking investors to join us on this exciting journey as we continue to redefine the future of diagnostics. By investing in EMPE Diagnostics, you will be supporting a company that not only has the potential for significant financial returns but also a profound impact on global health.
Join Us in Transforming Global Health
Investing in EMPE Diagnostics is an opportunity to be part of a groundbreaking company that combines innovative technology with a mission-driven approach. We invite you to learn more about our vision, our products, and the exciting investment opportunities that lie ahead. Together, we can shape the future of diagnostics and improve healthcare outcomes worldwide.
For more information on our current investment opportunities, please contact our Investor Relations team.
For more information on our current investment opportunities, please contact our Investor Relations team.
Why Invest in EMPE Diagnostics?
1. Innovative Technology with Global Impact
EMPE Diagnostics specializes in molecular diagnostics, with a focus on rapid and low-cost solutions for infectious diseases like tuberculosis and drug-resistant pathogens. Our proprietary technologies enable healthcare providers to diagnose and treat patients more effectively, particularly in low-resource settings where traditional diagnostics are inaccessible. This global scalability and our focus on critical health issues position us at the forefront of the diagnostic revolution.
2. Proven Track Record and Expertise
Founded and led by industry pioneers and renowned experts in molecular biology, biochemistry, and healthcare management, EMPE Diagnostics has a solid foundation of scientific expertise. Our team has developed and patented innovative diagnostic solutions that are gaining recognition and adoption worldwide. With multiple spin-out companies and collaborations with top research institutions, EMPE Diagnostics is recognized as a leader in the biotech and healthcare space.
3. Strong Market Opportunity
The global diagnostics market is expected to grow exponentially in the coming years, driven by the increasing demand for precision medicine, the rise of drug-resistant infections, and the need for accessible healthcare solutions in developing countries. EMPE Diagnostics is uniquely positioned to capitalize on these trends by offering products that meet the needs of both developed and emerging markets.
4. Socially Responsible and Impact-Oriented
At the heart of EMPE Diagnostics is a commitment to social impact. Our solutions address some of the world’s most pressing health issues, particularly in underserved regions where early diagnosis can save lives. By investing in EMPE, you are not only backing a high-growth company but also supporting a mission to bring life-saving diagnostics to populations that need them the most.
5. Scalable Business Model
Our innovative diagnostic platforms are designed to be affordable, portable, and easy to use, ensuring that they can be rapidly deployed across a wide range of settings, from hospitals and clinics to remote locations. This scalability offers significant revenue potential, especially as we expand into new markets and partner with healthcare providers and governments around the world.
EMPE Diagnostics specializes in molecular diagnostics, with a focus on rapid and low-cost solutions for infectious diseases like tuberculosis and drug-resistant pathogens. Our proprietary technologies enable healthcare providers to diagnose and treat patients more effectively, particularly in low-resource settings where traditional diagnostics are inaccessible. This global scalability and our focus on critical health issues position us at the forefront of the diagnostic revolution.
2. Proven Track Record and Expertise
Founded and led by industry pioneers and renowned experts in molecular biology, biochemistry, and healthcare management, EMPE Diagnostics has a solid foundation of scientific expertise. Our team has developed and patented innovative diagnostic solutions that are gaining recognition and adoption worldwide. With multiple spin-out companies and collaborations with top research institutions, EMPE Diagnostics is recognized as a leader in the biotech and healthcare space.
3. Strong Market Opportunity
The global diagnostics market is expected to grow exponentially in the coming years, driven by the increasing demand for precision medicine, the rise of drug-resistant infections, and the need for accessible healthcare solutions in developing countries. EMPE Diagnostics is uniquely positioned to capitalize on these trends by offering products that meet the needs of both developed and emerging markets.
4. Socially Responsible and Impact-Oriented
At the heart of EMPE Diagnostics is a commitment to social impact. Our solutions address some of the world’s most pressing health issues, particularly in underserved regions where early diagnosis can save lives. By investing in EMPE, you are not only backing a high-growth company but also supporting a mission to bring life-saving diagnostics to populations that need them the most.
5. Scalable Business Model
Our innovative diagnostic platforms are designed to be affordable, portable, and easy to use, ensuring that they can be rapidly deployed across a wide range of settings, from hospitals and clinics to remote locations. This scalability offers significant revenue potential, especially as we expand into new markets and partner with healthcare providers and governments around the world.
Our Growth Strategy
1. Product Development and Expansion:
We are continuously investing in the development of new diagnostic tests to address a broader range of infectious diseases. Our product pipeline is robust, with several innovations in the works that will further enhance our market presence.
2. Strategic Partnerships:
EMPE Diagnostics is actively forging partnerships with healthcare providers, NGOs, and government organizations to ensure widespread adoption of our diagnostic solutions. These collaborations not only accelerate product rollout but also position us as a trusted partner in the global healthcare ecosystem.
3. Global Market Penetration:
While we have a strong presence in Europe and Asia, we are aggressively expanding our market reach to other regions, including Africa and South America, where the need for cost-effective diagnostics is greatest.
4. Sustainability and Innovation:
We are committed to sustainable business practices and continuous innovation. By integrating sustainability into our operations and product development, we ensure that our solutions have a long-lasting impact on both global health and the environment.
We are continuously investing in the development of new diagnostic tests to address a broader range of infectious diseases. Our product pipeline is robust, with several innovations in the works that will further enhance our market presence.
2. Strategic Partnerships:
EMPE Diagnostics is actively forging partnerships with healthcare providers, NGOs, and government organizations to ensure widespread adoption of our diagnostic solutions. These collaborations not only accelerate product rollout but also position us as a trusted partner in the global healthcare ecosystem.
3. Global Market Penetration:
While we have a strong presence in Europe and Asia, we are aggressively expanding our market reach to other regions, including Africa and South America, where the need for cost-effective diagnostics is greatest.
4. Sustainability and Innovation:
We are committed to sustainable business practices and continuous innovation. By integrating sustainability into our operations and product development, we ensure that our solutions have a long-lasting impact on both global health and the environment.
Financial Performance and Future Outlook
EMPE Diagnostics has demonstrated strong financial performance, with consistent growth in revenue and market share. Our strategic investments in R&D, coupled with our global expansion efforts, are expected to drive substantial revenue growth in the coming years. With increasing demand for our products and the growing emphasis on healthcare innovation, EMPE Diagnostics is poised for long-term success.
We are inviting forward-thinking investors to join us on this exciting journey as we continue to redefine the future of diagnostics. By investing in EMPE Diagnostics, you will be supporting a company that not only has the potential for significant financial returns but also a profound impact on global health.
We are inviting forward-thinking investors to join us on this exciting journey as we continue to redefine the future of diagnostics. By investing in EMPE Diagnostics, you will be supporting a company that not only has the potential for significant financial returns but also a profound impact on global health.
Join Us in Transforming Global Health
Investing in EMPE Diagnostics is an opportunity to be part of a groundbreaking company that combines innovative technology with a mission-driven approach. We invite you to learn more about our vision, our products, and the exciting investment opportunities that lie ahead. Together, we can shape the future of diagnostics and improve healthcare outcomes worldwide.
For more information on our current investment opportunities, please contact our Investor Relations team.
For more information on our current investment opportunities, please contact our Investor Relations team.
At EMPE Diagnostics, we are pioneering a new era in the healthcare sector with a focus on rapid, affordable, and accessible diagnostic solutions for infectious diseases. Our mission is to revolutionize global health by developing and delivering innovative diagnostics that address urgent healthcare challenges, particularly in regions with limited access to advanced medical technologies.
As an investor in EMPE Diagnostics, you are not only contributing to a company that has a significant growth trajectory but also becoming part of a mission to improve healthcare outcomes for millions worldwide. Our innovative products have the potential to make a tangible impact on public health by enabling faster, more accurate diagnoses, which can lead to better treatment outcomes, reduced healthcare costs, and improved quality of life.
Why Invest in EMPE Diagnostics?
EMPE Diagnostics is redefining infectious disease diagnostics with rapid, affordable, and scalable solutions designed for global impact. As we approach market entry with breakthrough products, EMPE offers investors a rare opportunity to participate in both strong commercial growth and meaningful global health impact.
By investing in EMPE, you are backing a company poised to improve healthcare outcomes for millions—through faster, more accurate diagnosis that enables better treatment decisions, reduces system-wide healthcare costs, and improves quality of life worldwide.
1. Breakthrough Technology, Built for Scale
EMPE Diagnostics develops next-generation molecular diagnostics focused on TB and drug-resistant infections. Our proprietary, open-platform technologies integrate seamlessly into existing laboratory infrastructure, keeping adoption costs low and enabling rapid deployment. This makes our solutions uniquely suited for large-scale implementation, particularly in high-burden and resource-limited markets.
2. World-Class Scientific and Commercial Leadership
Founded on innovations from the Karolinska Institute, EMPE Diagnostics is led by a seasoned team of scientific and industry experts spanning molecular biology, biochemistry, and business development. This blend of deep science and commercial execution positions the company to successfully translate innovation into global market leadership.
3. Large, Underserved Market Opportunity
The molecular diagnostics market is growing rapidly, yet diseases prevalent in low and middle-income countries remain significantly underserved. Large multinational players often overlook these markets due to pricing and cost constraints. EMPE Diagnostics fills this gap with a cost-efficient operating model anchored in India. With ISO 13485:2016-certified manufacturing facility/plant in Hyderabad, India and local sales and marketing, EMPE benefits from strong margins and scalable economics.
4. Strong Impact with Commercial Returns
EMPE Diagnostics delivers measurable social impact while pursuing attractive investor returns. Our diagnostics address critical unmet medical needs, enabling earlier detection and more effective treatment in regions where timely diagnosis can save lives. This alignment of impact and profitability strengthens long-term value creation.
5. Flexible Business Model with Expansion Potential
Our platforms are designed for affordability, ease of use, and compatibility with standard molecular lab equipment, allowing deployment across hospitals, clinics, and decentralized settings. This flexibility supports rapid expansion across India and into global markets, unlocking multiple revenue streams and long-term growth potential.
EMPE Diagnostics represents a compelling investment at the intersection of cutting-edge science, scalable economics, and global health impact.
By investing in EMPE, you are backing a company poised to improve healthcare outcomes for millions—through faster, more accurate diagnosis that enables better treatment decisions, reduces system-wide healthcare costs, and improves quality of life worldwide.
1. Breakthrough Technology, Built for Scale
EMPE Diagnostics develops next-generation molecular diagnostics focused on TB and drug-resistant infections. Our proprietary, open-platform technologies integrate seamlessly into existing laboratory infrastructure, keeping adoption costs low and enabling rapid deployment. This makes our solutions uniquely suited for large-scale implementation, particularly in high-burden and resource-limited markets.
2. World-Class Scientific and Commercial Leadership
Founded on innovations from the Karolinska Institute, EMPE Diagnostics is led by a seasoned team of scientific and industry experts spanning molecular biology, biochemistry, and business development. This blend of deep science and commercial execution positions the company to successfully translate innovation into global market leadership.
3. Large, Underserved Market Opportunity
The molecular diagnostics market is growing rapidly, yet diseases prevalent in low and middle-income countries remain significantly underserved. Large multinational players often overlook these markets due to pricing and cost constraints. EMPE Diagnostics fills this gap with a cost-efficient operating model anchored in India. With ISO 13485:2016-certified manufacturing facility/plant in Hyderabad, India and local sales and marketing, EMPE benefits from strong margins and scalable economics.
4. Strong Impact with Commercial Returns
EMPE Diagnostics delivers measurable social impact while pursuing attractive investor returns. Our diagnostics address critical unmet medical needs, enabling earlier detection and more effective treatment in regions where timely diagnosis can save lives. This alignment of impact and profitability strengthens long-term value creation.
5. Flexible Business Model with Expansion Potential
Our platforms are designed for affordability, ease of use, and compatibility with standard molecular lab equipment, allowing deployment across hospitals, clinics, and decentralized settings. This flexibility supports rapid expansion across India and into global markets, unlocking multiple revenue streams and long-term growth potential.
EMPE Diagnostics represents a compelling investment at the intersection of cutting-edge science, scalable economics, and global health impact.
Our Growth Strategy
Our Growth Strategy
1. Product Development and Expansion:
Our CDSCO approved MDR-TB test has now been complemented with a range of new products spanning from TBDx – a fast and reliable TB +/- screening test to MDR and pre-XDR in qPCR format adding significant improvements to the original MDR-TB test. Most interestingly the new tests will be sold as freeze-dried products which will simplify logistics significantly. With these tests we seed the basis for a strong market expansion in response to the requirements from clinicians, regulatory bodies and governments. Beyond TB we are in contact with international organisations issuing requirements for tests in high demand for low and middle-income countries.
2. Strategic Partnerships:
EMPE Diagnostics has over time received development grants from international organisations such as Gates Foundation and the EIC and is actively working with international organisations to expand our global reach as well as for funding of new product initiatives.
We are over time building an international presence with support from these organisations and are seeking non-dilutive grants to expand our capacity.
3. Global Market Penetration:
While we from our commercial base in India also enjoy a strong presence in Asia, we are actively looking to expand our market reach to Africa, where the need for cost-effective diagnostics is huge. Expansion is to some extent governed by which countries will allow for a smooth approval process. In that context, we are also working with WHO to obtain endorsement and eventually WHO Prequalification (PQ) which in turn will pave the way for a smoother expansion in many of the export territories.
1. Product Development and Expansion:
Our CDSCO approved MDR-TB test has now been complemented with a range of new products spanning from TBDx – a fast and reliable TB +/- screening test to MDR and pre-XDR in qPCR format adding significant improvements to the original MDR-TB test. Most interestingly the new tests will be sold as freeze-dried products which will simplify logistics significantly. With these tests we seed the basis for a strong market expansion in response to the requirements from clinicians, regulatory bodies and governments. Beyond TB we are in contact with international organisations issuing requirements for tests in high demand for low and middle-income countries.
2. Strategic Partnerships:
EMPE Diagnostics has over time received development grants from international organisations such as Gates Foundation and the EIC and is actively working with international organisations to expand our global reach as well as for funding of new product initiatives.
We are over time building an international presence with support from these organisations and are seeking non-dilutive grants to expand our capacity.
3. Global Market Penetration:
While we from our commercial base in India also enjoy a strong presence in Asia, we are actively looking to expand our market reach to Africa, where the need for cost-effective diagnostics is huge. Expansion is to some extent governed by which countries will allow for a smooth approval process. In that context, we are also working with WHO to obtain endorsement and eventually WHO Prequalification (PQ) which in turn will pave the way for a smoother expansion in many of the export territories.
Financial Performance and Future Outlook
EMPE Diagnostics has built strong, defensible value through a combination of differentiated technology, regulatory maturity, and capital-efficient operations. Our padlock probe–based platform enables highly complex AMR genotyping, while our ISO 13485:2016–certified manufacturing facility in Hyderabad—re-certified with outstanding results in July 2025—demonstrates a robust and consistently high-performing quality system.
Recent product launches confirm our ability to develop and commercialize new diagnostics rapidly and cost-effectively, guided by close collaboration with clinicians to ensure clear clinical relevance and fast market adoption.
With most of our cost base in India, EMPE benefits from exceptional unit economics across manufacturing and commercialization. This allows investor capital to directly fuel large-scale growth. Under conservative assumptions, the company is positioned to reach cash-flow positivity within two years of investment by capturing just 3% of the Indian market.
Built on realistic, disciplined financial planning and supported by strong international interest—particularly from Africa and Southeast Asia—EMPE Diagnostics offers investors a clear path to scalable growth, early profitability, and meaningful global health impact.
Recent product launches confirm our ability to develop and commercialize new diagnostics rapidly and cost-effectively, guided by close collaboration with clinicians to ensure clear clinical relevance and fast market adoption.
With most of our cost base in India, EMPE benefits from exceptional unit economics across manufacturing and commercialization. This allows investor capital to directly fuel large-scale growth. Under conservative assumptions, the company is positioned to reach cash-flow positivity within two years of investment by capturing just 3% of the Indian market.
Built on realistic, disciplined financial planning and supported by strong international interest—particularly from Africa and Southeast Asia—EMPE Diagnostics offers investors a clear path to scalable growth, early profitability, and meaningful global health impact.
